Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.64 |
| ▸ | CDK2 | P24941 | 13/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309467 | 0.89 | GSK3B (0.67) | GSK3BCDK2CCNA2CCNA1SYK | |
| SCHEMBL11931063 | 0.88 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1CDK1 | |
| SCHEMBL13885032 | 0.84 | GSK3B (0.79) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13308740 | 0.82 | GSK3B (0.76) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13309248 | 0.78 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13308741 | 0.78 | GSK3B (0.57) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13893732 | 0.77 | GSK3B (0.83) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13998502 | 0.77 | GSK3B (0.87) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13308746 | 0.77 | GSK3B (0.51) | GSK3BCDK2CCNA2CCNA1CDK1 | |
| SCHEMBL11931064 | 0.77 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759531-B2 | Preparation method of fluoro-substituted deuterated diphenylurea | Suzhou Zelgen Biopharmaccceutical Co., Ltd. (CN) | 2014-06-24 | — | — | US | disclosed |
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |